References
- Leebeck F and Miesbach W. Gene
therapy for hemophilia: a review on clinical benefit, limitations, and
remaining issues. Blood 2021; 138(11):923-931.
- Nathwani A. Gene therapy for hemophilia. Hematology 2022 ;
ASH Education Program: 569-578.
- Hover L. Hemophilia A. N Engl J Med 1994; 330(1): 38-47.
- Mannucci P and Tuddenham E. The Hemophilias – From Royal Genes to
Gene Therapy. N Engl J Med 2001; 344(23): 1773-1779.
- Anson D, Hock R, Austen D, Smith K, Brownlee G, Verma I, Miller D.
Towards Gene Therapy for Hemophilia B. Mol Biol Med 1987; 4:
11-20.
- Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R
et al. Prophylaxis versus Episodic Treatment to Prevent Joint Disease
in Boys with Severe Hemophilia. N Engl J Med 2007; 357(6):
535-544.
- Di Michele D. Immune tolerance induction in haemophilia: evidence and
the way forward. J Thromb Haemost 2011; 9(Suppl. 1): 216-225.
- Ljung R. The risk associated with indwelling catheters in children
with haemophilia. Br J Haematol 2007; 138: 580-586.
- Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch P, Hanabusa
H, Oldenburg J et al. Long-acting recombinant coagulation factor IX
albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3
trial. Blood 2016; 127(14): 1761-1769.
- Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger I et
al. Phase 3 study of recombinant factor VIII Fc fusion protein in
severe hemophilia A. Blood 2014; 123(3): 317-325.
- Von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle B, Oldenburg
J et al. Efanesoctocog Alfa prophylaxis for patients with severe
hemophilia A. N Engl J Med 2023; 388: 310-318
- Mahlangu J, Oldenburg J, Paz-Priel, Negrier C, Niggli H, Mancuso M et
al. Emicizumab Prophylaxis in Patients Who Have Hemophilia without
Inhibitors. N Engl J Med 2018; 379 (9): 811-822.
- Young G, Liesner R, Chang T, Sidonio R, Oldenburg J Jimenez-Yuste V et
al. A multicenter, open-label phase 3 study of emicizumab prophylaxis
in children with hemophilia A with inhibitors. Blood 2019;
134(24): 2127-2138.
- Nogami K and Shima M. Current and future therapies for haemophilia –
Beyond factor replacement therapies. Br J Haematol 2023;
200:23-34.
- Hassan S, Monahan R, Mauser-Bunschoten E, van Vulpen L, Eikenboom J
Beckers E et al. Mortality, life expectancy, and cause of death of
persons with hemophilia in the Netherlands 2001-2018. J Thromb
Haemost 2021; 19: 645-653.
- Frei-Jones M, Cepo K, d’Oiron R, Sim Goh A, Mathias M, Odgaard-Jensen
J. Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A
or B with Inhibitors: Efficacy and Safety Results by Hemophilia
Subtype from Phase 3 Explorer 7 Trial. Blood 2022; 140 (Suppl 1):
466-468.
- Young G, Srivastava A, Kavakli K, Ross C, Sathar J, Tran H et al.
Efficacy and Safety of Fitusiran Prophylaxis, a siRNA Therapeutic, in
a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or
B, with Inhibitors (PwHI). Blood 2021; 138 (Suppl 1): 4.
- Mahhitt L, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Nadhi S et al.
Nirsevimab for Prevention of
RSV in Healthy Late-Preterm and
Term Infants. N Engl J Med 2022; 386(9): 837-846.
- Dover S, Blanchette V, Wrathall D, Pullenayegum E, Kazandjian D, Song
B et al. Hemophilia prophylaxis adherence and bleeding using a
tailored, frequency-escalated approach: The Canadian Hemophilia
Primary Prophylaxis Study. Res Pract Thromb Haemost 2020 ;
4:318-325.
- National Hemophilia Foundation. Stimate Recall Update. [cited 2022
DEC 22] from: https://www.hemophilia.org/news/stimate-recall-update
- Abbattista M, Ciavarella A, Noone D, Peyvandi F. Hemorrhagic and
thrombotic adverse events associated with Emicizumab and extended
half-life factor VIII replacement drugs: EudraVigilance data of 2021.J Thromb Haemost 2023; 21: 5460552.
- Bolous N, Chen Y, Wang H, Davidoff A, Devidas M, Jacobs T et al. The
cost-effectiveness of gene therapy for severe hemophilia B: a
microsimulation study from the United States perspective. Blood2021; 138(18) 1677-1690.
- Thornburg C. Prepare the Way for Hemophilia A Gene Therapy. N
Engl J Med 2022; 386(11): 1081-1082.
- Mahlangu J, Kaczmarek R, von Drygalski A, Shapriro S, Chou C, Ozelo M
et al. Two-Year Outcomes of Valoctocogene Roxaparvovec therapy for
hemophilia A. N Engl J Med 2023; 388: 694-705.
- Pipe S, Leebek F, Recht M, Key N, Castaman G Miesbach S et al. Gene
therapy with Etranacogene Dezaparvovec for hemophilia B. N Engl
J Med 2023; 388: 706-718.
- Pierce G and Herzog R. Two gene therapies for hemophilia available:
Now What? Mol Ther 2023; 31: 919-920.
- Shah J, Kim H, Sivamurthy K, Monahan P, Fries H. Comprehensive
analysis and prediction of
long-term durability of factor IX activity following etranacogene
dezaparvovec gene therapy in the treatment of hemophilia B.Current Med Research and Opinion 2022
- Samelson-Jones B and George L. Adeno-associated virus gene therapy for
hemophilia. Annu Rev Med 2023; 74:16.1-16.7.
- Carter B. Adeno-associated virus and the development of
adeno-associated virus vectors: a historical perspective. Mol
Ther 2004; 10, 981–989.
- Nault J, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G et al.
Recurrent AAV2-related insertional mutagenesis in human hepatocellular
carcinomas. Nat Genet 2015; 47(10): 1187-1195.
- Russell D and Grompe M. Adeno-associated virus finds its disease.Nat Genet 2015; 47(10): 1104-1105.
- Buening H and Schmidt M. Adeno-associated Vector Toxicity-To Be or Not
to Be? Mol Ther 2015 23(11): 1673-1675.
- Dave U and Cornetta K. AAV Joins the Rank of Genotoxic Vectors.Mol Ther 2021; 29(2): 418-419.
- Chandler R, Sands M, and Venditti C. Recombinant Adeno-Associated
Viral Integration and Genotoxicity: Insights from Animal Models.Hum Gene Ther 2017; 28(4): 314-322.
- Monahan P, Negrier C, Tarantino M, Valentino L, Mingozzi F. Emerging
Immunogenicity and Genotoxicity of Adeno-Associated Virus Vector Gene
Therapy for Hemophilia. J Clin Med 2021; 10: 2471
- Dalwadi D, Torrens L. Abril-Fornaguera J, Pinyol R, Willoughby C,
Posey J et al. Liver Injury Increases the Incidence of HCC following
AAV Gene Therapy in Mice. Mol Ther 2021; 29(2): 680-690.
- Nguyen G, Everett J, Kafle S, Roche A, Raymond H, Leiby J et al. A
long-term study of AAV gene therapy in dogs with hemophilia A
identifies clonal expansions of transduced liver cells. Nat
Biotechnol 2021; 39: 47-55.
- Batty P, Mo A, Hurlbut D, Ishida B, Yates B, Brown C et al. Long-term
follow-up of liver-directed, adeno-associated vector-mediated gene
therapy in the canine model of hemophilia A. Blood 2022;
140(25): 2673-2683.
- Sabatino D, Bushman F, Chandler R, Crystal R, Davidson B, Dolmetsch R
et al. Evaluating the state of the science for adeno-associated virus
integration: An integrated perspective. Mol Ther 2022; 30(8):
2646-2663.
- Niemeyer G, Herzog R, Mount J, Arruda V, Tillson D, Hathcock J et al.
Long-term correction of inhibitor-prone hemophilia B dogs treated with
liver-directed AAV2-mediated factor IX gene therapy. Blood2009; 133(4): 797-806.
- Fong S, Yates B, Sihn C, Mattis A, Mitchell N, Liu S et al.
Interindividual variability in transgene mRNA and protein production
following adeno-associated virus gene therapy for hemophilia A.Nat Medicine 2022; 28: 789-797.
- Dalwadi D, Calabria A, Tiyaboonchai A, Posey J, Naugler W, Montini E
et al. AAV integration in human hepatocytes. Mol Ther 2021;
29(10): 2898-2909.
- Konkle B, Walsh C, Escobar M, Josephson N, Young G, von Drygalski A et
al. BAX 335 hemophilia B gene therapy clinical trial results:
potential impact of CpG sequences on gene expression. Blood2021; 137(6): 763-774.
- National Hemophilia Foundation.
Biomarin announced an additional serious adverse event in its gene
therapy clinical trial for haemophiia A. [cited 2022 DEC 22] from:
https://www.hemophilia.org/sites/default/files/document/files/2022_09_12_Joint-Statement-on-BioMarin-SAE-in-GT%20Trial_FINAL.pdf.
- Gorder L, Doshi B, Willis E, Lanza M, Arruda V, Callan M et al. Vector
Analysis of Multicentric Lymphoma in a Severe Hemophilia A Dog after
AAV Gene Therapy. Blood 2022; 140(Suppl 1): 4919-4920.
- Fahs S, Hille M, Shi Q, Weiler H, Montgomery R. A conditional knockout
mouse model reveals endothelial cells as the principal and possible
exclusive source of plasma factor VIII. Blood 2014; 123(24):
3706-3713.
- Poothong J, Pottekat A, Siirin M, Campos A, Paton A, Paton J et al.
Factor VIII exhibits chaperone-dependent and glucose-regulated
reversible amyloid formation in the endoplasmic reticulum. Blood
2020;135(21): 1899-1911.
- Lange A, Altynova E, Nguyen G, Sabatino D. Overexpression of factor
VIII after AAV delivery is transiently associated with cellular stress
in hemophilia A mice. Mol Ther 2016; 3: 16064.
- Butterfield J, Yamada K, Bertolini T, Syed F, Kumar S, Li X et al.
Il-15 blockade, and rapamycin rescue multifactorial loss of factor
VIII from AAV-transduced hepatocytes in hemophilia A mice. Mol
Ther 30; 12: 3552-3569.
- Kapelanski-Lamoureaux A, Chen Z, Gao Z, Deng R, Lasaris A, Lebeaupin C
et al. Ectopic expression and misfolding in hepatocytes as a cause for
hepatocellular carcinoma. Mol Ther 2022; 30: 3524-3551.
- Mendell J, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T et
al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.N Engl J Med 2017; 377(18): 1713-1722.
- Day J, Mendell J, Mercuri E, Finkel R, Strauss K, Kleyn A et al.
Clinical Trial and Post marketing Safety of Onasemnogene Abeparvovec
Therapy. Drug Safety 2021; $$: 1109-1119.
- Ertl H. Immunogenicity and toxicity of AAV gene therapy. Front
Immunol 2022; 13: 975803
- United States Food and Drug
Administration Adverse Events Reporting System (FAERS) Public
Dashboard. Search Zolgensma. [cited 2022 DEC 22) from:
https://fis.fda.gov.
- Pagliarulo N. Novartis reports deaths of two patients treated with
Zolgensma gene therapy. [cited 2022 DEC 22] from:
https://www.biopharmadive.com/news/novartis-zolgensma-patient-death-liver-injury/629542/
- Coratti G, Cutrona C, Pera M, Bovis F, Ponzano M, Chieppa F et al.
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a
critical review and meta-analysis. Orphanet J Rare Dis 2021;
16:430.
- Genentech. New Data for Genentech’s Evrysdi (risdiplam) Demonstrates
Long-Term Efficacy and Safety in a Broad Population of People with
Spinal Muscular Atrophy [cited 2022 DEC 29]
fromhttps://www.gene.com/media/press-releases/14945/2022-03-15/new-data-for-genentechs-evrysdi-risdipla
- Ribero V, Daigl M, Marti Y, Gorni K, Evans R, Scott A et al. How does
risdiplam compare with other treatments for Types 1-3 spinal muscular
atrophy: a systematic literature review and indirect treatment
comparison. J Comp Eff Res 2022; 11(5): 347-370.
- Hordeaux J, Buza E, Dyer C, Goode T, Mitchell T, Richman L et al.
Adeno-Associated Virus Induced Dorsal Root Ganglion Pathology.Hum Gene Ther 2021; 31(15 and 16): 808-819.
- Buss N, Lanigan L, Zeller J, Cissell D, Metea M, Adams E.
Characterization of AAV-mediated dorsal root ganglionopathy. Mol Ther
2022; 24: 342-354.
- Sidonio R, Pipe S, Callaghan M, Valentino L, Monahan P, Croteau S.
Discussion investigational AAV gene therapy with hemophilia patients:
A guide. Blood Rev 2021; 47:100759.
- Mannucci P. Hemophilia treatment innovations: 50 years of progress and
more to come. J Thromb Haemost 2023; 21: 403-412.
- Murphy L, Schwartz T, Helmick C, Renner J, Tudor G, Koch G et al.
Lifetime Risk of Symptomatic Knee Osteoarthritis. Arthritis
Rheum 2008; 59(9): 1207-1213.